癌症管理中的基因问题：多聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的适应症变化》（The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer）。

IF 1.4 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Clinical obstetrics and gynecology Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI:10.1097/GRF.0000000000000896

Christine Walsh

{"title":"癌症管理中的基因问题：多聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的适应症变化》（The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer）。","authors":"Christine Walsh","doi":"10.1097/GRF.0000000000000896","DOIUrl":null,"url":null,"abstract":"Between December 2014 and May 2020, the United States Food and Drug Administration approved 9 indications for poly (ADP-ribose) polymerase (PARP) inhibitor use in ovarian cancer. Between June 2022 and September 2022, all 3 indications for PARP inhibitor treatment of recurrent ovarian cancer were withdrawn. Between November 2022 and September 2023, all 3 indications for PARP inhibitor maintenance therapy in recurrent ovarian cancer were restricted. The 3 indications for PARP inhibitor maintenance therapy in newly diagnosed advanced ovarian cancer are unchanged. This article reviews the timelines and data leading to regulatory changes for PARP inhibitor use in ovarian cancer in the United States.","PeriodicalId":10415,"journal":{"name":"Clinical obstetrics and gynecology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495477/pdf/","citationCount":"0","resultStr":"{\"title\":\"Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer.\",\"authors\":\"Christine Walsh\",\"doi\":\"10.1097/GRF.0000000000000896\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Between December 2014 and May 2020, the United States Food and Drug Administration approved 9 indications for poly (ADP-ribose) polymerase (PARP) inhibitor use in ovarian cancer. Between June 2022 and September 2022, all 3 indications for PARP inhibitor treatment of recurrent ovarian cancer were withdrawn. Between November 2022 and September 2023, all 3 indications for PARP inhibitor maintenance therapy in recurrent ovarian cancer were restricted. The 3 indications for PARP inhibitor maintenance therapy in newly diagnosed advanced ovarian cancer are unchanged. This article reviews the timelines and data leading to regulatory changes for PARP inhibitor use in ovarian cancer in the United States.\",\"PeriodicalId\":10415,\"journal\":{\"name\":\"Clinical obstetrics and gynecology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495477/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical obstetrics and gynecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/GRF.0000000000000896\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical obstetrics and gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GRF.0000000000000896","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

2014 年 12 月至 2020 年 5 月期间，美国食品和药物管理局批准了 9 个聚合（ADP-核糖）聚合酶（PARP）抑制剂治疗卵巢癌的适应症。2022 年 6 月至 2022 年 9 月，PARP 抑制剂治疗复发性卵巢癌的 3 个适应症全部撤销。2022 年 11 月至 2023 年 9 月期间，限制了 PARP 抑制剂维持治疗复发性卵巢癌的全部 3 个适应症。PARP 抑制剂维持治疗新诊断晚期卵巢癌的 3 个适应症保持不变。本文回顾了导致美国PARP抑制剂用于卵巢癌的法规变化的时间表和数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer.

Between December 2014 and May 2020, the United States Food and Drug Administration approved 9 indications for poly (ADP-ribose) polymerase (PARP) inhibitor use in ovarian cancer. Between June 2022 and September 2022, all 3 indications for PARP inhibitor treatment of recurrent ovarian cancer were withdrawn. Between November 2022 and September 2023, all 3 indications for PARP inhibitor maintenance therapy in recurrent ovarian cancer were restricted. The 3 indications for PARP inhibitor maintenance therapy in newly diagnosed advanced ovarian cancer are unchanged. This article reviews the timelines and data leading to regulatory changes for PARP inhibitor use in ovarian cancer in the United States.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical obstetrics and gynecology 医学-妇产科学

CiteScore

2.70

自引率

0.00%

发文量

186

审稿时长

3 months

期刊介绍： Each issue of Clinical Obstetrics and Gynecology is a complete symposium on one or two timely topics of interest in obstetrics and gynecology. For each quarterly issue, two prominent guest editors solicit contributions on key clinical topics of interest to practicing physicians. Procedures, current clinical problems, medical and surgical treatments, and effective diagnostic aids are all carefully reviewed in original articles. The result is an instructive resource that dispenses trustworthy clinical guidance that enhances your understanding of key areas of your practice.